Exelixis, Teva settle Cabometyx patent litigation with 2031 generic license

[cafead]

via With stalwart cancer drug Cabometyx driving its commercial performance, Exelixis has put plenty of effort behind defending the drug's intellectual property. Now, a patent deal with generics giant Teva adds one more layer to its defenses.

article source